New hope for HER2+ breast cancer: switching drug combos after treatment fails
NCT ID NCT07455188
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at what happens when people with HER2-positive advanced breast cancer switch between two different targeted therapy combinations after their first treatment stops working. About 600 women will be split into two groups: one switches from HP+chemo to HPy+chemo, the other does the opposite. The goal is to see which switch works better at controlling the cancer and helping people live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
RECRUITINGZhejiang, Hangzhou, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?